Display:
Providers:
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Today's News, July 06, 2022 | ||
---|---|---|
July 01, 2022 | ||
June 29, 2022 | ||
June 24, 2022 | ||
June 07, 2022 | ||
June 02, 2022 | ||
May 31, 2022 | ||
May 21, 2022 | ||
May 20, 2022 | ||
May 17, 2022 | ||
May 02, 2022 | ||
April 20, 2022 | ||
April 19, 2022 | ||
Next > |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2022. All rights reserved.